Luc Marengere
Managing Partner @ TVM Capital Life Science
Montréal, Canada
Luc Marengere is a venture - series unknown investor at TVM Capital Life Science in Montréal focused on Medical Device and Health Care. Marengere oversees the establishment of the new Canadian operations and the North American investment strategy as well as deal sourcing and execution. Marengere joins TVM Capital after more than 15 years of venture capital experience in Canada and the U.S. Most recently, Marengere was a Managing General Partner with VG Partners where hesuccessfully launched and oversaw the operations and investments of the VG Advanced Life Sciences Fund (VG ALSF).Luc was a Director on the Boards of Trillium Technologies Inc., (Toronto, ON); Cytochroma Inc., (Toronto, ON); Aegera Therapeutics, Inc. (Montréal, QC); Cita Neuropharma (sold to Vernalis Plc, UK), (Toronto, ON) and lastly Argos Therapeutics Inc., (Durham, NC). Luc also invested in VisualSonics, Inc. (sold to U.S.-based SonoSite), (Toronto, ON). Prior to joining VG Partners, he focused on making venture investments in the life science sector while with CDP Capital – Technology Ventures and MDS Capital Corp.Prior to his venture capital career, he conducted commercially-oriented research in the fields of immunology and oncology while at Amgen. He holds a Ph.D. from University of Toronto’s department of Medical Biophysics and Molecular Genetics.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 73%
Last updated:
For AI agents: llms.txt
Industries Luc Marengere invests in
Stages Luc Marengere invests in
Countries Luc Marengere invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical Device 7 (64%)
- Health Care 6 (55%)
- Biotechnology 3 (27%)
- Manufacturing 3 (27%)
- Medical 2 (18%)
Stage
- Venture - Series Unknown 5 (45%)
- Series C 2 (18%)
- Series A 1 (9%)
- Series B 1 (9%)
- Series D 1 (9%)
Country
- United States 5 (45%)
- Canada 3 (27%)
- United Kingdom 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Egg Medical is a medical device company that offers EGGNEST, a passive protection designed to drastically reduce scatter radiation exposure for the entire cath lab team without disruption to workflow. It is an in integrated work platform built on a carbon fiber sled base designed to drastically reduce scatter radiation exposure without disruptingworkflow. | $14.3M / Mar 01, 2025 | ||
| CSA Medical provides cryotherapy systems. It offers CryoSpray Ablation system, which enables the physicians to freeze, destroy, and remove unwanted tissues, as well as transports liquid nitrogen that is passed through a standard endoscope. CSA Medical was formerly known as Crymed Technologies and changed its name to CSA Medical in April 2006.Thecompany was incorporated in 1993 and is based in Lutherville Timonium, Maryland. | $53M / Series D / Sep 09, 2024 | ||
| Headquartered in San Diego, Vektor Medical is on a mission to revolutionize arrhythmia care for millions affected by atrial fibrillation and other arrhythmias. Through its AI-based, non-invasive arrhythmia analysis technology, vMap, the company aims to improve cardiac ablation outcomes, optimize workflows, and increase procedural efficiency. | $25M / Series A / Feb 05, 2024 | ||
Recurv Pharma
|
Recurv Pharma's RP-001 is a novel chemical entity (NCE) that is administered in a nano-emulsion formulation, concentrating medication delivery to the tumour while preserving healthy organs. Strong efficacy in a variety of pre-clinical tumour models, including non-small cell lung, breast, ovarian, prostate, pancreatic, and colorectal cancers,has allowed the chemical to show that it can destroy tumours even in multi-drug resistant tumours. | $24M / Venture - Series Unknown / Feb 01, 2023 | |
| Egg Medical is a medical device company that offers EGGNEST, a passive protection designed to drastically reduce scatter radiation exposure for the entire cath lab team without disruption to workflow. It is an in integrated work platform built on a carbon fiber sled base designed to drastically reduce scatter radiation exposure without disruptingworkflow. | $13M / Venture - Series Unknown / Feb 26, 2022 | ||
| Access Vascular has developed a disruptive technology using a novel material process intended to significantly reduce the blood component accumulation (thrombosis or blood clotting) that leads to occlusions and infections. Over the last three years, Access Vascular’s technology has demonstrated the potential for superior clinical outcomes and lowerhealthcare costs compared with existing technologies. For patients, their solutions are predicted to decrease morbidity, shorten hospital stays, advance treatment, and minimize pain.Their technology has the potential to address a range of clinical needs in a variety of indications. Access Vascular is focused initially on launching their HydroPICC, a peripherally inserted central catheter with superior material performance over the current lagging technology. | $20M / Series B / Mar 03, 2021 | ||
| Kent Imaging is an innovator in multispectral oxygenation imaging, designs, manufactures, and markets imaging technology to improve plastic surgery, colorectal surgery, trauma, wound care, limb salvage, podiatry, burns, and cardiac specialties. The team at Kent Imaging is committed to improving patient outcomes by delivering innovative andpractical solutions for the healthcare industry. Kent Imaging holds multiple patents in medical technology and is currently commercializing the breakthrough multispectral imaging solutions that assess tissue oxygen saturation. The company is headquartered in Calgary, Alberta, Canada, and has locations in Chicago, Los Angeles, Salt Lake City, and Seattle. | $15M / Venture - Series Unknown / Feb 12, 2021 | ||
| Emovi is a company offering medical solutions for joints assessments. Emovi is dedicated to providing the highest quality, most technologically advanced products for knee joint assessment to restore patient quality of life. they are a company of knowledgeable, dedicated team members committed to innovation in healthcare. | $11.3M / Series C / Mar 04, 2019 | ||
| Founded in 2011 by brothers Gabriel and Bernard Robichaud, Panthera Dental is a leader in prosthetic implant solutions and dental sleep appliances. Employing more than 50, the Québec City firm also has an office in New Jersey. | Venture - Series Unknown / Oct 03, 2017 | ||
| Ixchelsis Ltd is a clinical-stage biotechnology company developing an oxytocin receptor antagonist (IX-01) for the treatment of premature ejaculation (PE). IX-01 is a clinical stage asset that has the potential to be the best in class pharmacological approach for the treatment of PE. To date IX-01 has completed a Phase 1 single ascending dose studyin healthy male volunteers and is currently being progressed through to clinical proof of concept (POC). Ixchelsis is funded by TVM Life Sciences Ventures VII and is lead by an excellent Management team with extensive experience in pharmaceutical R&D, particularly in the male sexual health therapeutic area. | $12M / Venture - Series Unknown / Dec 05, 2016 | ||
| See all 11 investments → | |||
Co-Investors
About TVM Capital Life Science
TVM Capital Life Science is a dedicated life science venture capital firm, with offices in Montreal, Canada and Munich, Germany. Since inception, TVM Capital Life Science has invested in entrepreneurial venture backed companies. Over several fund generations, their investment strategy has included a multi-stage investment approach spanningdiscovery to market ready companies as well as profitable companies searching for growth capital. Their investment focus has always been broad and includes investments in therapeutics, technology platforms, medtech and diagnostics. They invest in Canada, the U.S., Germany and Western Europe with their dedicated team of investment professionals based in Montreal and Munich.
TVM Capital Life Science Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Catello Somma
Associate
|
|||
Hubert Birner
Managing Partner
|
|||
|
Luc Marengere
Managing Partner
|
|||
Marc Riviere
General Partner
|
|||
Sascha Berger
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Luc Marengere invest in?
Luc Marengere invests primarily in Medical Device, Health Care and Biotechnology startups, most often at Venture - Series Unknown and Series C stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Luc Marengere?
Public channels for Luc Marengere include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Luc Marengere last invest?
The most recent investment recorded for Luc Marengere closed in Mar 2025. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
